Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

Immunity

Volumn 44, Issue 6, 2016, Pages 1255-1269

  Pitt, Jonathan M ^a,b,c   Vétizou, Mari ^a,b,c   Daillère, Romain ^a,b,c   Roberti, María Paula ^a,b   Yamazaki, Takahiro ^a,b   Routy, Bertrand ^a,b,c   Lepage, Patricia ^d   Boneca, Ivo Gomperts ^e,f   Chamaillard, Mathias ^g   Kroemer, Guido ^{h,i,j,k,l,m,n}   Zitvogel, Laurence ^a,b,c,o  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b University Paris XI   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d UMR1319 MICALIS   (France)

^e INSTITUT PASTEUR   (France)

^f INSERM   (France)

^g UNIV LILLE   (France)

^h Institut Gustave Roussy   (France)

ⁱ Metabolomics and Cell Biology Platforms   (France)

^j CENTRE DE RECHERCHE DES CORDELIERS   (France)

^k HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^l UNIVERSITÉ PARIS DESCARTES   (France)

^m SORBONNE UNIVERSITÉ   (France)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^o CBT 507 Centre of Clinical Investigations   (France)

more..

Author keywords

Cancer; CTLA 4; Immune checkpoint blockade; Immunotherapy; Immunotherapy resistance; Ipilimumab; Microbiome; Microbiota; PD 1; PD L1

Indexed keywords

CHEMOKINE; CPG OLIGODEOXYNUCLEOTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR;

CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CELL STRESS; CYTOKINE RELEASE; DIET; EPIGENETICS; HLA TYPING; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; INTESTINE FLORA; METABOLIC REGULATION; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TH1 TH2 BALANCE; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES; TUMOR ESCAPE;

ANIMALS; ANTIBODIES, MONOCLONAL; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84975059616     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2016.06.001     Document Type: Review

References (167)

1. Akbay E.A., Koyama S., Carretero J., Altabef A., Tchaicha J.H., Christensen C.L., Mikse O.R., Cherniack A.D., Beauchamp E.M., Pugh T.J., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013, 3:1355-1363.
2. Ansell S.M., Lesokhin A.M., Borrello I., Halwani A., Scott E.C., Gutierrez M., Schuster S.J., Millenson M.M., Cattry D., Freeman G.J., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 2015, 372:311-319.
3. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
4. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., Frees K., Watt J.L., Schwartz D.A. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 2000, 25:187-191.
5. Arpaia N., Campbell C., Fan X., Dikiy S., van der Veeken J., deRoos P., Liu H., Cross J.R., Pfeffer K., Coffer P.J., Rudensky A.Y. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013, 504:451-455.
6. Atarashi K., Tanoue T., Shima T., Imaoka A., Kuwahara T., Momose Y., Cheng G., Yamasaki S., Saito T., Ohba Y., et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011, 331:337-341.
7. Atarashi K., Tanoue T., Oshima K., Suda W., Nagano Y., Nishikawa H., Fukuda S., Saito T., Narushima S., Hase K., et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013, 500:232-236.
8. Auclair J., Frappier M., Millette M. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): Characterization, Manufacture, Mechanisms of Action, and Quality Control of a Specific Probiotic Combination for Primary Prevention of Clostridium difficile Infection. Clin. Infect. Dis. 2015, 60(Suppl 2):S135-S143.
9. Bald T., Landsberg J., Lopez-Ramos D., Renn M., Glodde N., Jansen P., Gaffal E., Steitz J., Tolba R., Kalinke U., et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 2014, 4:674-687.
10. Barreira da Silva R., Laird M.E., Yatim N., Fiette L., Ingersoll M.A., Albert M.L. Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat. Immunol. 2015, 16:850-858.
11. Beck K.E., Blansfield J.A., Tran K.Q., Feldman A.L., Hughes M.S., Royal R.E., Kammula U.S., Topalian S.L., Sherry R.M., Kleiner D., et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 2006, 24:2283-2289.
12. Belkaid Y., Hand T.W. Role of the microbiota in immunity and inflammation. Cell 2014, 157:121-141.
13. Berman D., Parker S.M., Siegel J., Chasalow S.D., Weber J., Galbraith S., Targan S.R., Wang H.L. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010, 10:11.
14. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., Linn S.C., Gonzalez-Angulo A.M., Stemke-Hale K., Hauptmann M., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
15. Biedermann L., Zeitz J., Mwinyi J., Sutter-Minder E., Rehman A., Ott S.J., Steurer-Stey C., Frei A., Frei P., Scharl M., et al. Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. PLoS ONE 2013, 8:e59260.
16. Bindea G., Mlecnik B., Tosolini M., Kirilovsky A., Waldner M., Obenauf A.C., Angell H., Fredriksen T., Lafontaine L., Berger A., et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013, 39:782-795.
17. Bioley G., Guillaume P., Luescher I., Yeh A., Dupont B., Bhardwaj N., Mears G., Old L.J., Valmori D., Ayyoub M. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine. Clin. Cancer Res. 2009, 15:299-306.
18. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366:2455-2465.
19. Broz M.L., Binnewies M., Boldajipour B., Nelson A.E., Pollack J.L., Erle D.J., Barczak A., Rosenblum M.D., Daud A., Barber D.L., et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 2014, 26:638-652.
20. Buqué A., Bloy N., Aranda F., Castoldi F., Eggermont A., Cremer I., Fridman W.H., Fucikova J., Galon J., Marabelle A., et al. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. OncoImmunology 2015, 4:e1008814.
21. Burrows M.P., Volchkov P., Kobayashi K.S., Chervonsky A.V. Microbiota regulates type 1 diabetes through Toll-like receptors. Proc. Natl. Acad. Sci. USA 2015, 112:9973-9977.
22. Casrouge A., Decalf J., Ahloulay M., Lababidi C., Mansour H., Vallet-Pichard A., Mallet V., Mottez E., Mapes J., Fontanet A., et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J. Clin. Invest. 2011, 121:308-317.
23. Chang C.H., Qiu J., O'Sullivan D., Buck M.D., Noguchi T., Curtis J.D., Chen Q., Gindin M., Gubin M.M., van der Windt G.J., et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell 2015, 162:1229-1241.
24. Chen D.N., Song C.G., Yu K.D., Jiang Y.Z., Ye F.G., Shao Z.M. A Prospective Evaluation of the Association between a Single Nucleotide Polymorphism rs3775291 in Toll-Like Receptor 3 and Breast Cancer Relapse. PLoS ONE 2015, 10:e0133184.
25. Coombes J.L., Siddiqui K.R., Arancibia-Cárcamo C.V., Hall J., Sun C.M., Belkaid Y., Powrie F. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J. Exp. Med. 2007, 204:1757-1764.
26. Corrales L., Gajewski T.F. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer. Clin. Cancer Res. 2015, 21:4774-4779.
27. Cotillard A., Kennedy S.P., Kong L.C., Prifti E., Pons N., Le Chatelier E., Almeida M., Quinquis B., Levenez F., Galleron N., et al. Dietary intervention impact on gut microbial gene richness. Nature 2013, 500:585-588. ANR MicroObes consortium.
28. Coussens L.M., Zitvogel L., Palucka A.K. Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 2013, 339:286-291.
29. Dalal S.R., Chang E.B. The microbial basis of inflammatory bowel diseases. J. Clin. Invest. 2014, 124:4190-4196.
30. Dapito D.H., Mencin A., Gwak G.Y., Pradere J.P., Jang M.K., Mederacke I., Caviglia J.M., Khiabanian H., Adeyemi A., Bataller R., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012, 21:504-516.
31. Dasgupta S., Erturk-Hasdemir D., Ochoa-Reparaz J., Reinecker H.C., Kasper D.L. Plasmacytoid dendritic cells mediate anti-inflammatory responses to a gut commensal molecule via both innate and adaptive mechanisms. Cell Host Microbe 2014, 15:413-423.
32. Deng L., Liang H., Xu M., Yang X., Burnette B., Arina A., Li X.D., Mauceri H., Beckett M., Darga T., et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity 2014, 41:843-852.
33. Diamond M.S., Kinder M., Matsushita H., Mashayekhi M., Dunn G.P., Archambault J.M., Lee H., Arthur C.D., White J.M., Kalinke U., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 2011, 208:1989-2003.
34. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Roche P.C., Lu J., Zhu G., Tamada K., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 2002, 8:793-800.
35. Dubin K., Callahan M.K., Ren B., Khanin R., Viale A., Ling L., No D., Gobourne A., Littmann E., Huttenhower C., et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun. 2016, 7:10391.
36. Dutoit V., Rubio-Godoy V., Pittet M.J., Zippelius A., Dietrich P.Y., Legal F.A., Guillaume P., Romero P., Cerottini J.C., Houghten R.A., et al. Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans. J. Exp. Med. 2002, 196:207-216.
37. Eberl G. A new vision of immunity: homeostasis of the superorganism. Mucosal Immunol. 2010, 3:450-460.
38. Fourcade J., Sun Z., Benallaoua M., Guillaume P., Luescher I.F., Sander C., Kirkwood J.M., Kuchroo V., Zarour H.M. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 2010, 207:2175-2186.
39. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L.J., Malenkovich N., Okazaki T., Byrne M.C., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000, 192:1027-1034.
40. Fridman W.H., Pagès F., Sautès-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012, 12:298-306.
41. Fucikova J., Becht E., Iribarren K., Goc J., Remark R., Damotte D., Alifano M., Devi P., Biton J., Germain C., et al. Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis. Cancer Res. 2016, 76:1746-1756.
42. Fuertes M.B., Kacha A.K., Kline J., Woo S.R., Kranz D.M., Murphy K.M., Gajewski T.F. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells. J. Exp. Med. 2011, 208:2005-2016.
43. Fulop T., Larbi A., Kotb R., de Angelis F., Pawelec G. Aging, immunity, and cancer. Discov. Med. 2011, 11:537-550.
44. Furusawa Y., Obata Y., Fukuda S., Endo T.A., Nakato G., Takahashi D., Nakanishi Y., Uetake C., Kato K., Kato T., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013, 504:446-450.
45. Galluzzi L., Buqué A., Kepp O., Zitvogel L., Kroemer G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell 2015, 28:690-714.
46. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., Tosolini M., Camus M., Berger A., Wind P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
47. Galon J., Angell H.K., Bedognetti D., Marincola F.M. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013, 39:11-26.
48. Gao Q., Wang X.Y., Qiu S.J., Yamato I., Sho M., Nakajima Y., Zhou J., Li B.Z., Shi Y.H., Xiao Y.S., et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin. Cancer Res. 2009, 15:971-979.
49. Garrett W.S. Cancer and the microbiota. Science 2015, 348:80-86.
50. Gophna U. Microbiology. The guts of dietary habits. Science 2011, 334:45-46.
51. Goronzy J.J., Weyand C.M. Understanding immunosenescence to improve responses to vaccines. Nat. Immunol. 2013, 14:428-436.
52. Goto Y., Panea C., Nakato G., Cebula A., Lee C., Diez M.G., Laufer T.M., Ignatowicz L., Ivanov I.I. Segmented filamentous bacteria antigens presented by intestinal dendritic cells drive mucosal Th17 cell differentiation. Immunity 2014, 40:594-607.
53. Gubin M.M., Zhang X., Schuster H., Caron E., Ward J.P., Noguchi T., Ivanova Y., Hundal J., Arthur C.D., Krebber W.J., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515:577-581.
54. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013, 369:134-144.
55. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
56. Hargreaves C.E., Rose-Zerilli M.J., Machado L.R., Iriyama C., Hollox E.J., Cragg M.S., Strefford J.C. Fcγ receptors: genetic variation, function, and disease. Immunol. Rev. 2015, 268:6-24.
57. Haworth K.B., Leddon J.L., Chen C.Y., Horwitz E.M., Mackall C.L., Cripe T.P. Going back to class I: MHC and immunotherapies for childhood cancer. Pediatr. Blood Cancer 2015, 62:571-576.
58. Herbst R.S., Soria J.C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S., Sosman J.A., McDermott D.F., Powderly J.D., Gettinger S.N., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
59. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
60. Holmgaard R.B., Zamarin D., Munn D.H., Wolchok J.D., Allison J.P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 2013, 210:1389-1402.
61. Hursting S.D., Berger N.A. Energy balance, host-related factors, and cancer progression. J. Clin. Oncol. 2010, 28:4058-4065.
62. Iida N., Dzutsev A., Stewart C.A., Smith L., Bouladoux N., Weingarten R.A., Molina D.A., Salcedo R., Back T., Cramer S., et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013, 342:967-970.
63. Ivanov I.I., Atarashi K., Manel N., Brodie E.L., Shima T., Karaoz U., Wei D., Goldfarb K.C., Santee C.A., Lynch S.V., et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009, 139:485-498.
64. Joyce J.A., Fearon D.T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015, 348:74-80.
65. Kabouridis P.S., Pachnis V. Emerging roles of gut microbiota and the immune system in the development of the enteric nervous system. J. Clin. Invest. 2015, 125:956-964.
66. Kamada N., Seo S.U., Chen G.Y., Núñez G. Role of the gut microbiota in immunity and inflammatory disease. Nat. Rev. Immunol. 2013, 13:321-335.
67. Kroemer G., Galluzzi L., Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 2013, 31:51-72.
68. Kroemer G., Senovilla L., Galluzzi L., André F., Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nat. Med. 2015, 21:1128-1138.
69. Krummel M.F., Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 1995, 182:459-465.
70. Ladoire S., Penault-Llorca F., Senovilla L., Dalban C., Enot D., Locher C., Prada N., Poirier-Colame V., Chaba K., Arnould L., et al. Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. Autophagy 2015, 11:1878-1890.
71. Lagier J.C., Hugon P., Khelaifia S., Fournier P.E., La Scola B., Raoult D. The rebirth of culture in microbiology through the example of culturomics to study human gut microbiota. Clin. Microbiol. Rev. 2015, 28:237-264.
72. Le D.T., Uram J.N., Wang H., Bartlett B.R., Kemberling H., Eyring A.D., Skora A.D., Luber B.S., Azad N.S., Laheru D., et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 2015, 372:2509-2520.
73. Le Chatelier E., Nielsen T., Qin J., Prifti E., Hildebrand F., Falony G., Almeida M., Arumugam M., Batto J.M., Kennedy S., et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013, 500:541-546. MetaHIT consortium.
74. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736.
75. Lee Y.K., Menezes J.S., Umesaki Y., Mazmanian S.K. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 2011, 108(Suppl 1):4615-4622.
76. Li J., Jia H., Cai X., Zhong H., Feng Q., Sunagawa S., Arumugam M., Kultima J.R., Prifti E., Nielsen T., et al. An integrated catalog of reference genes in the human gut microbiome. Nat. Biotechnol. 2014, 32:834-841. MetaHIT Consortium, MetaHIT ConsortiumMetaHIT Consortium.
77. Lin A., Bik E.M., Costello E.K., Dethlefsen L., Haque R., Relman D.A., Singh U. Distinct distal gut microbiome diversity and composition in healthy children from Bangladesh and the United States. PLoS ONE 2013, 8:e53838.
78. López-Albaitero A., Lee S.C., Morgan S., Grandis J.R., Gooding W.E., Ferrone S., Ferris R.L. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol. Immunother. 2009, 58:1853-1864.
79. Louis P., Hold G.L., Flint H.J. The gut microbiota, bacterial metabolites and colorectal cancer. Nat. Rev. Microbiol. 2014, 12:661-672.
80. Malmberg K.J., Lenkei R., Petersson M., Ohlum T., Ichihara F., Glimelius B., Frödin J.E., Masucci G., Kiessling R. A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer. Clin. Cancer Res. 2002, 8:1772-1778.
81. Marabelle A., Kohrt H., Sagiv-Barfi I., Ajami B., Axtell R.C., Zhou G., Rajapaksa R., Green M.R., Torchia J., Brody J., et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J. Clin. Invest. 2013, 123:2447-2463.
82. Martens A., Wistuba-Hamprecht K., Foppen M.G., Yuan J., Postow M.A., Wong P., Romano E., Khammari A., Dreno B., Capone M., et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin. Cancer Res. 2016, Published online January 19, 2016. 10.1158/1078-0432.CCR-15-2412.
83. Mathur H., Rea M.C., Cotter P.D., Ross R.P., Hill C. The potential for emerging therapeutic options for Clostridium difficile infection. Gut Microbes 2014, 5:696-710.
84. Matsushita H., Vesely M.D., Koboldt D.C., Rickert C.G., Uppaluri R., Magrini V.J., Arthur C.D., White J.M., Chen Y.S., Shea L.K., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482:400-404.
85. Mazmanian S.K., Round J.L., Kasper D.L. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008, 453:620-625.
86. Ménétrier-Caux C., Curiel T., Faget J., Manuel M., Caux C., Zou W. Targeting regulatory T cells. Target. Oncol. 2012, 7:15-28.
87. Meyer C., Cagnon L., Costa-Nunes C.M., Baumgaertner P., Montandon N., Leyvraz L., Michielin O., Romano E., Speiser D.E. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother. 2014, 63:247-257.
88. Mitchell M.S., Harel W., Groshen S. Association of HLA phenotype with response to active specific immunotherapy of melanoma. J. Clin. Oncol. 1992, 10:1158-1164.
89. Morton A.M., Sefik E., Upadhyay R., Weissleder R., Benoist C., Mathis D. Endoscopic photoconversion reveals unexpectedly broad leukocyte trafficking to and from the gut. Proc. Natl. Acad. Sci. USA 2014, 111:6696-6701.
90. Mucida D., Park Y., Kim G., Turovskaya O., Scott I., Kronenberg M., Cheroutre H. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007, 317:256-260.
91. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., Laccabue D., Zerbini A., Camisa R., Bisagni G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 2008, 26:1789-1796.
92. Nagarsheth N., Peng D., Kryczek I., Wu K., Li W., Zhao E., Zhao L., Wei S., Frankel T., Vatan L., et al. PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer. Cancer Res. 2016, 76:275-282.
93. Ngiow S.F., Young A., Jacquelot N., Yamazaki T., Enot D., Zitvogel L., Smyth M.J. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res. 2015, 75:3800-3811.
94. Nielsen H.B., Almeida M., Juncker A.S., Rasmussen S., Li J., Sunagawa S., Plichta D.R., Gautier L., Pedersen A.G., Le Chatelier E., et al. Identification and assembly of genomes and genetic elements in complex metagenomic samples without using reference genomes. Nat. Biotechnol. 2014, 32:822-828. MetaHIT Consortium, MetaHIT ConsortiumMetaHIT Consortium.
95. Nishijima T.F., Muss H.B., Shachar S.S., Moschos S.J. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. Cancer Treat. Rev. 2016, 45:30-37.
96. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
97. Parsa A.T., Waldron J.S., Panner A., Crane C.A., Parney I.F., Barry J.J., Cachola K.E., Murray J.C., Tihan T., Jensen M.C., et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 2007, 13:84-88.
98. Pawelec G., Derhovanessian E., Larbi A. Immunosenescence and cancer. Crit. Rev. Oncol. Hematol. 2010, 75:165-172.
99. Peng D., Kryczek I., Nagarsheth N., Zhao L., Wei S., Wang W., Sun Y., Zhao E., Vatan L., Szeliga W., et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 2015, 527:249-253.
100. Peng W., Chen J.Q., Liu C., Malu S., Creasy C., Tetzlaff M.T., Xu C., McKenzie J.A., Zhang C., Liang X., et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016, 6:202-216.
101. Pfirschke C., Engblom C., Rickelt S., Cortez-Retamozo V., Garris C., Pucci F., Yamazaki T., Poirier-Colame V., Newton A., Redouane Y., et al. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity 2016, 44:343-354.
102. Platten M., Wick W., Van den Eynde B.J. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 2012, 72:5435-5440.
103. Postow M.A., Callahan M.K., Wolchok J.D. Immune Checkpoint Blockade in Cancer Therapy. J. Clin. Oncol. 2015, 33:1974-1982.
104. Ragab D., Laird M., Duffy D., Casrouge A., Mamdouh R., Abass A., Shenawy D.E., Shebl A.M., Elkashef W.F., Zalata K.R., et al. CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients. Cytokine 2013, 63:105-112.
105. Rescigno M. A 'fit' microbiota to potentiate cancer immunotherapy. Genome Med. 2015, 7:131.
106. Riva A., Laird M., Casrouge A., Ambrozaitis A., Williams R., Naoumov N.V., Albert M.L., Chokshi S. Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection. Hepatology 2014, 60:487-496.
107. Rizvi N.A., Hellmann M.D., Snyder A., Kvistborg P., Makarov V., Havel J.J., Lee W., Yuan J., Wong P., Ho T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015, 348:124-128.
108. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J.F., Testori A., Grob J.J., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364:2517-2526.
109. Round J.L., Lee S.M., Li J., Tran G., Jabri B., Chatila T.A., Mazmanian S.K. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 2011, 332:974-977.
110. Rubio-Godoy V., Dutoit V., Zhao Y., Simon R., Guillaume P., Houghten R., Romero P., Cerottini J.C., Pinilla C., Valmori D. Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL. J. Immunol. 2002, 169:5696-5707.
111. Rutkowski M.R., Stephen T.L., Svoronos N., Allegrezza M.J., Tesone A.J., Perales-Puchalt A., Brencicova E., Escovar-Fadul X., Nguyen J.M., Cadungog M.G., et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 2015, 27:27-40.
112. Sakuishi K., Apetoh L., Sullivan J.M., Blazar B.R., Kuchroo V.K., Anderson A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 2010, 207:2187-2194.
113. Sandel M.H., Dadabayev A.R., Menon A.G., Morreau H., Melief C.J., Offringa R., van der Burg S.H., Janssen-van Rhijn C.M., Ensink N.G., Tollenaar R.A., et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin. Cancer Res. 2005, 11:2576-2582.
114. Santegoets S.J., Stam A.G., Lougheed S.M., Gall H., Jooss K., Sacks N., Hege K., Lowy I., Scheper R.J., Gerritsen W.R., et al. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J. Immunother. Cancer 2014, 2:31.
115. Schadendorf D., Ugurel S., Schuler-Thurner B., Nestle F.O., Enk A., Bröcker E.B., Grabbe S., Rittgen W., Edler L., Sucker A., et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann. Oncol. 2006, 17:563-570. DC study group of the DeCOG.
116. Schildberg F.A., Klein S.R., Freeman G.J., Sharpe A.H. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity 2016, 44:955-972.
117. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
118. Schumacher T.N., Schreiber R.D. Neoantigens in cancer immunotherapy. Science 2015, 348:69-74.
119. Sender R., Fuchs S., Milo R. Revised estimates for the number of human and bacteria cells in the body. bioRxiv 2016, 10.1101/036103.
120. Sharma P., Allison J.P. The future of immune checkpoint therapy. Science 2015, 348:56-61.
121. Sharma P., Allison J.P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015, 161:205-214.
122. Simpson T.R., Li F., Montalvo-Ortiz W., Sepulveda M.A., Bergerhoff K., Arce F., Roddie C., Henry J.Y., Yagita H., Wolchok J.D., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 2013, 210:1695-1710.
123. Sistigu A., Yamazaki T., Vacchelli E., Chaba K., Enot D.P., Adam J., Vitale I., Goubar A., Baracco E.E., Remédios C., et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 2014, 20:1301-1309.
124. Sivan A., Corrales L., Hubert N., Williams J.B., Aquino-Michaels K., Earley Z.M., Benyamin F.W., Lei Y.M., Jabri B., Alegre M.L., et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015, 350:1084-1089.
125. Smith P.M., Howitt M.R., Panikov N., Michaud M., Gallini C.A., Bohlooly-Y M., Glickman J.N., Garrett W.S. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013, 341:569-573.
126. Snyder A., Makarov V., Merghoub T., Yuan J., Zaretsky J.M., Desrichard A., Walsh L.A., Postow M.A., Wong P., Ho T.S., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014, 371:2189-2199.
127. Spencer M.D., Hamp T.J., Reid R.W., Fischer L.M., Zeisel S.H., Fodor A.A. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011, 140:976-986.
128. Spranger S., Spaapen R.M., Zha Y., Williams J., Meng Y., Ha T.T., Gajewski T.F. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med. 2013, 5:200ra116.
129. Spranger S., Koblish H.K., Horton B., Scherle P.A., Newton R., Gajewski T.F. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J. Immunother. Cancer 2014, 2:3.
130. Spranger S., Bao R., Gajewski T.F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 2015, 523:231-235.
131. Sun C.M., Hall J.A., Blank R.B., Bouladoux N., Oukka M., Mora J.R., Belkaid Y. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J. Exp. Med. 2007, 204:1775-1785.
132. Tarhini A.A., Butterfield L.H., Shuai Y., Gooding W.E., Kalinski P., Kirkwood J.M. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination. J. Immunother. 2012, 35:702-710.
133. Tarhini A.A., Cherian J., Moschos S.J., Tawbi H.A., Shuai Y., Gooding W.E., Sander C., Kirkwood J.M. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J. Clin. Oncol. 2012, 30:322-328.
134. Taube J.M., Klein A., Brahmer J.R., Xu H., Pan X., Kim J.H., Chen L., Pardoll D.M., Topalian S.L., Anders R.A. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 2014, 20:5064-5074.
135. Tesniere A., Schlemmer F., Boige V., Kepp O., Martins I., Ghiringhelli F., Aymeric L., Michaud M., Apetoh L., Barault L., et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010, 29:482-491.
136. Tomihara K., Curiel T.J., Zhang B. Optimization of immunotherapy in elderly cancer patients. Crit. Rev. Oncog. 2013, 18:573-583.
137. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
138. Topalian S.L., Wolchok J.D., Chan T.A., Mellman I., Palucka K., Banchereau J., Rosenberg S.A., Dane Wittrup K. Immunotherapy: The path to win the war on cancer?. Cell 2015, 161:185-186.
139. Touchefeu Y., Montassier E., Nieman K., Gastinne T., Potel G., Bruley des Varannes S., Le Vacon F., de La Cochetière M.F. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis - current evidence and potential clinical applications. Aliment. Pharmacol. Ther. 2014, 40:409-421.
140. Tran E., Ahmadzadeh M., Lu Y.C., Gros A., Turcotte S., Robbins P.F., Gartner J.J., Zheng Z., Li Y.F., Ray S., et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 2015, 350:1387-1390.
141. Tumeh P.C., Harview C.L., Yearley J.H., Shintaku I.P., Taylor E.J., Robert L., Chmielowski B., Spasic M., Henry G., Ciobanu V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515:568-571.
142. Turnbaugh P.J., Hamady M., Yatsunenko T., Cantarel B.L., Duncan A., Ley R.E., Sogin M.L., Jones W.J., Roe B.A., Affourtit J.P., et al. A core gut microbiome in obese and lean twins. Nature 2009, 457:480-484.
143. Turnbaugh P.J., Ridaura V.K., Faith J.J., Rey F.E., Knight R., Gordon J.I. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci. Transl. Med. 2009, 1:6ra14.
144. Ubeda C., Pamer E.G. Antibiotics, microbiota, and immune defense. Trends Immunol. 2012, 33:459-466.
145. Vacchelli E., Ma Y., Baracco E.E., Sistigu A., Enot D.P., Pietrocola F., Yang H., Adjemian S., Chaba K., Semeraro M., et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science 2015, 350:972-978.
146. Van Allen E.M., Miao D., Schilling B., Shukla S.A., Blank C., Zimmer L., Sucker A., Hillen U., Geukes Foppen M.H., Goldinger S.M., et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015, 350:207-211.
147. van Rooij N., van Buuren M.M., Philips D., Velds A., Toebes M., Heemskerk B., van Dijk L.J., Behjati S., Hilkmann H., El Atmioui D., et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 2013, 31:e439-e442.
148. Velicer C.M., Heckbert S.R., Lampe J.W., Potter J.D., Robertson C.A., Taplin S.H. Antibiotic use in relation to the risk of breast cancer. JAMA 2004, 291:827-835.
149. Vétizou M., Pitt J.M., Daillère R., Lepage P., Waldschmitt N., Flament C., Rusakiewicz S., Routy B., Roberti M.P., Duong C.P., et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015, 350:1079-1084.
150. Viaud S., Saccheri F., Mignot G., Yamazaki T., Daillère R., Hannani D., Enot D.P., Pfirschke C., Engblom C., Pittet M.J., et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013, 342:971-976.
151. Wallace B.D., Wang H., Lane K.T., Scott J.E., Orans J., Koo J.S., Venkatesh M., Jobin C., Yeh L.A., Mani S., Redinbo M.R. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010, 330:831-835.
152. Walunas T.L., Lenschow D.J., Bakker C.Y., Linsley P.S., Freeman G.J., Green J.M., Thompson C.B., Bluestone J.A. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994, 1:405-413.
153. Wang J.L., Chang C.H., Lin J.W., Wu L.C., Chuang L.M., Lai M.S. Infection, antibiotic therapy and risk of colorectal cancer: a nationwide nested case-control study in patients with Type 2 diabetes mellitus. Int. J. Cancer 2014, 135:956-967.
154. Weber J.S., Kähler K.C., Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 2012, 30:2691-2697.
155. Woo S.R., Turnis M.E., Goldberg M.V., Bankoti J., Selby M., Nirschl C.J., Bettini M.L., Gravano D.M., Vogel P., Liu C.L., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012, 72:917-927.
156. Woo S.R., Fuertes M.B., Corrales L., Spranger S., Furdyna M.J., Leung M.Y., Duggan R., Wang Y., Barber G.N., Fitzgerald K.A., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014, 41:830-842.
157. Wu H.J., Ivanov I.I., Darce J., Hattori K., Shima T., Umesaki Y., Littman D.R., Benoist C., Mathis D. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010, 32:815-827.
158. Wu G.D., Chen J., Hoffmann C., Bittinger K., Chen Y.Y., Keilbaugh S.A., Bewtra M., Knights D., Walters W.A., Knight R., et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011, 334:105-108.
159. Xiao Y., Yu S., Zhu B., Bedoret D., Bu X., Francisco L.M., Hua P., Duke-Cohan J.S., Umetsu D.T., Sharpe A.H., et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J. Exp. Med. 2014, 211:943-959.
160. Xuan C., Shamonki J.M., Chung A., Dinome M.L., Chung M., Sieling P.A., Lee D.J. Microbial dysbiosis is associated with human breast cancer. PLoS ONE 2014, 9:e83744.
161. Yang W., Bai Y., Xiong Y., Zhang J., Chen S., Zheng X., Meng X., Li L., Wang J., Xu C., et al. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature 2016, 531:651-655.
162. Yatsunenko T., Rey F.E., Manary M.J., Trehan I., Dominguez-Bello M.G., Contreras M., Magris M., Hidalgo G., Baldassano R.N., Anokhin A.P., et al. Human gut microbiome viewed across age and geography. Nature 2012, 486:222-227.
163. Yoshimoto S., Loo T.M., Atarashi K., Kanda H., Sato S., Oyadomari S., Iwakura Y., Oshima K., Morita H., Hattori M., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013, 499:97-101.
164. Zelenay S., van der Veen A.G., Böttcher J.P., Snelgrove K.J., Rogers N., Acton S.E., Chakravarty P., Girotti M.R., Marais R., Quezada S.A., et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell 2015, 162:1257-1270.
165. Zitvogel L., Galluzzi L., Viaud S., Vétizou M., Daillère R., Merad M., Kroemer G. Cancer and the gut microbiota: an unexpected link. Sci. Transl. Med. 2015, 7:271ps1.
166. Zitvogel L., Ayyoub M., Routy B., Kroemer G. Microbiome and Anticancer Immunosurveillance. Cell 2016, 165:276-287.
167. Zou W., Wolchok J.D., Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 2016, 8:328rv4.